Genzyme reports new survival data with clofarabine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Genzyme updated information for their CLASSIC II investigational study on Clolar (clofarabine). The estimated median overall survival data was 72 weeks for patients achieving complete remission, the company said.

Genzyme updated information for their CLASSIC II investigational study on Clolar (clofarabine). The estimated median overall survival data was 72 weeks for patients achieving complete remission, the company said. The estimated median survival for acute myeloid leukemia patients achieving overall remission was 59 weeks. The new estimated median duration of remission data and disease-free survival data suggest Clolar produced durable remissions in the patient population, according to the company.

Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells
Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
Related Content
Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

Roman Fabbricatore
November 18th 2025
Article

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

Tim Cortese
November 17th 2025
Article

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?

Tim Cortese
November 16th 2025
Article

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.